Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis

Theodora Bejan-Angoulvant (1) , David Ternant (1) , Fadela Daoued , Frédéric Medina , Louis Bernard (2) , Saloua Mammou , Gilles Paintaud (1) , Denis Mulleman (1)

1 GICC UMR 7292 CNRS - Génétique, immunothérapie, chimie et cancer (GICC), UMR 7292 CNRS [2012-2017]
2 Service des Maladies Infectieuses

Tumor necrosis factor inhibitors are effective in reducing inflammation in rheumatic diseases but increase the risk of infections. This study was undertaken to investigate the relationship between the trough serum concentration of infliximab (IFX) and the risk of a first infection episode.

Domains: Life Sciences [q-bio]; Human health and pathology; Life Sciences [q-bio]; Human health and pathology; Rhumatology and musculoskeletal system; Life Sciences [q-bio]; Human health and pathology; Infectious diseases; Life Sciences [q-bio]; Pharmaceutical sciences; Pharmacology

Theodora Bejan-Angoulvant, David Ternant, Fadela Daoued, Frédéric Medina, Louis Bernard, et al.. Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis. Arthritis & rheumatology, 2017, 69 (1), pp.108-113. ⟨10.1002/art.39841⟩. ⟨hal-01980809⟩